Related Experiment Video
Updated: May 7, 2026
A Gaze-Contingent Display Framework for Perceptual Learning Research with Simulated Central Vision Loss
Published on: April 11, 2025
Visual rehabilitation in patients with myopic maculopathy: our experience
Enzo Maria Vingolo1, Serena Salvatore, Daniela Domanico
1Department of Ophthalmology, University La Sapienza of Rome, Rome;; UOC of Ophthalmology, AUSL Latina, Ospedale Fiorini Terracina, Latina, Italy.
Objective:
To evaluate the efficacy of the MP-1 microperimeter (Nidek Technologies Srl, Padova, Italy) and Visual Pathfinder (LACE Inc) in improving visual function of patients with myopic maculopathy.
Design:
Prospective, nonrandomized, interventional case series.
Participants:
Seventeen patients (34 eyes) between 36 and 58 years of age with myopic maculopathy and central retinal scotomas.
Methods:
After a complete eye examination, all patients underwent 10 training sessions with MP-1 biofeedback (7 minutes) and Visual Pathfinder (3 minutes) for each eye once a week. Statistical analysis was performed with Student t test. The p values less than 0.05 were considered statistically significant.
Results:
The mean best corrected visual acuity increased from 0.64 ± 0.22 to 0.38 ± 0.20 logMAR at the end of follow-up (p = 0.03); visual-evoked potential P100 amplitude increased from 3.54 ± 1.90 to 6.64 ± 2.91 μV at the end of follow-up (p = 0.04); average retinal sensitivity, calculated in the 12 degrees of the central retina, increased from 6.6 ± 2.6 to 14.6 ± 3.6 dB (p = 0.03). Fixation behaviour in the 2 degrees of the central retina increased from 45% ± 17% to 75% ± 23% (p = 0.04). The bivariate contour ellipse area (95%) increased from 10.34 ± 3.11 to 7.64 ± 2.71 square degrees (p = 0.04).
Conclusions:
The combination of acoustic biofeedback training with MP-1 and Visual Pathfinder offers a reasonable improvement of visual function in patients with myopic maculopathy. This method might be considered as a rehabilitative strategy as a "therapeutic option" in these patients for whom most treatments usually do not work.
